AI Article Synopsis
- Breast cancer is the most common cancer among women, with 20-30% of patients facing metastasis after surgery and poor treatment responses despite advancements in therapies.
- CAR-T cell therapy, a promising immunotherapy, struggles with solid tumors like breast cancer due to the complexity of the tumor environment and a lack of ideal targets.
- The text discusses potential targets for CAR-T therapy in breast cancer (like HER-2 and EGFR), addresses challenges (such as off-target effects and tumor microenvironment issues), and suggests strategies to enhance this treatment approach.
Article Abstract
Breast cancer is the leading cancer in women. Around 20-30% breast cancer patients undergo invasion or metastasis after radical surgical resection and eventually die. Number of breast cancer patients show poor sensitivity toward treatments despite the advances in chemotherapy, endocrine therapy, and molecular targeted treatments. Therapeutic resistance and tumor recurrence or metastasis develop with the ongoing treatments. Conducive treatment strategies are thus required. Chimeric antigen receptor (CAR)-modified T-cell therapy has progressed as a part of tumor immunotherapy. However, CAR-T treatment has not been effective in solid tumors because of tumor microenvironment complexity, inhibitory effects of extracellular matrix, and lacking ideal tumor antigens. Herein, the prospects of CAR-T cell therapy for metastatic breast cancer are discussed, and the targets for CAR-T therapy in breast cancer (HER-2, C-MET, MSLN, CEA, MUC1, ROR1, EGFR) at clinical level are reviewed. Moreover, solutions are proposed for the challenges of breast cancer CAR-T therapy regarding off-target effects, heterogeneous antigen expression by tumor cells and immunosuppressive tumor microenvironment. Ideas for improving the therapeutics of CAR-T cell therapy in metastatic breast cancer are suggested.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2023.114648 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.
Acad Radiol
January 2025
Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No.150, Nangang District, Harbin 150081, China (Q-X.C., L-Q.Z., X-Y.W., H-X.Z., J-J.L., M-C.X., H-Y.S., Z-X.K.). Electronic address:
Rationale And Objectives: To propose a novel MRI-based hyper-fused radiomic approach to predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer (BC).
Materials And Methods: Pretreatment dynamic contrast-enhanced (DCE) MRI and ultra-multi-b-value (UMB) diffusion-weighted imaging (DWI) data were acquired in BC patients who received NAT followed by surgery at two centers. Hyper-fused radiomic features (RFs) and conventional RFs were extracted from DCE-MRI or UMB-DWI.
Predicting Late Recurrence in Male Estrogen Receptor-Positive Breast Cancer With Clinical Treatment Score Post-5 years: A SEER database analysis of 65,711 cases.
Clin Breast Cancer
December 2024
Comprehensive Breast Health Center, Zhejiang Provincial Hospital of Chinese Medicine, China. Electronic address:
Purpose: Male breast cancer is an understudied disease with unique clinicopathological features. This study aims to evaluate the predictive value of the Clinical Treatment Score post-5 years (CTS5) in estimating late recurrence risk in estrogen receptor-positive (ER+) male breast cancer patients.
Methods: This retrospective study includes 65,711 ER+ early male (n = 611) and female (n = 65,100) breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2018.
Risk reducing mastectomy in Norwegian BRCA1/2 carriers.
Eur J Surg Oncol
December 2024
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Background: Risk reducing mastectomy (RRM) is an option for women with pathogenic germline variants in BRCA1 or BRCA2 (BRCA1/2). This study investigates and compares RRM-uptake among Norwegian BRCA1/2 carriers from 2008 to 2021, temporal trends, and incidence of breast cancer (BC) after surgery.
Methods: BRCA1/2 carriers without prior breast or ovarian cancer, tested at Oslo University Hospital between January 1st 2008 and December 31st 2021 were included in the study.
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.
ESMO Open
January 2025
Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address:
Background: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.
Materials And Methods: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets.
Structural isomers of carene persuade apoptotic cell death by inhibiting cell cycle in breast cancer cells: An in silico and in vitro approach.
Tissue Cell
December 2024
Department of Food Science and Biotechnology, Sejong University, Gwangjin-gu, Seoul, Republic of Korea. Electronic address:
For the first time, our study provides a comprehensive examination of the anti-cancer effects of structural isomers of carene in breast cancer cells, specifically focusing on cell cycle inhibition and the induction of apoptosis. We utilized the hydro-distillation method to extract Piper nigrum seed essential oil (PNS-EO) and identified its bioactive components through gas chromatography-mass spectrometry (GC-MS) analysis. A total of 46 bioactive compounds were isolated via hydro-distillation, identified through GC-MS analysis, and validated by co-injection using GC analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!